Surface expression of CD192 is down-modulated even in the remission phase in MS, and down-modulation is rather enhanced by IFN-β therapy probably being one of the self-protective mechanisms against MS partly contributing to sustained remission by preventing monocyte infiltration into the CNS [53]. The gene discussed is IFNB1; the disease is myeloid sarcoma.